2021
DOI: 10.1007/s11605-020-04868-0
|View full text |Cite
|
Sign up to set email alerts
|

Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma

Abstract: Background Level 1 evidence for multimodal treatment of resectable gastric adenocarcinoma from the Intergroup 0116 (2001) and MAGIC (2006) trials demonstrated survival benefit of adjuvant chemoradiation (CRT) and perioperative chemotherapy, respectively. We evaluated the adoption of evidence-based treatment in the post-MAGIC era and its impact on survival. Methods A total of 7058 patients with resectable gastric adenocarcinoma undergoing definitive surgical resection be… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 26 publications
0
0
0
Order By: Relevance